ZURICH (Reuters) -Switzerland’s Roche will purchase U.S. biopharma agency Poseida Therapeutics in a money deal price up to $1.5 billion, the businesses mentioned on Tuesday.
Poseida is to be purchased at $9 per share in money, and stockholders may also obtain a non-tradeable contingent worth proper for up to $4 per share if particular milestones are met, taking the deal worth to up to round $1.5 billion.
It’s anticipated to shut within the first quarter of 2025.
“We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future programs,” mentioned Kristin Yarema, president and CEO of the San Diego-based Poseida, in an announcement.
Poseida and its staff will be a part of Roche as a part of the Swiss agency’s prescribed drugs division, Poseida mentioned.
The acquisition will set up a brand new functionality for Roche in allogeneic cell remedy, with alternatives centered on CAR-T packages coated by current collaboration between Poseida and Roche in hematologic malignancies, the U.S. agency mentioned.
It would embrace CAR-T packages for stable tumours and autoimmune ailments, together with Poseida’s genetic engineering platform and associated pre-clinical medicines, it added.